SCStephen G. Chaney

Stephen G. Chaney

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stephen G. Chaney has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Debio 0507 primarily forms diaminocyclohexane-Pt-d(GpG) and -d(ApG) DNA adducts in HCT116 cells

    by C. L. King, S. Ramachandran, S. G. Chaney, L. Collins, J. A. Swenberg, K. E. Dekrafft, W. Lin, L. Cicurel, M. Barbier


  • Open Access

    Flanking Bases Influence the Nature of DNA Distortion by Platinum 1,2-Intrastrand (GG) Cross-Links

    by Debadeep Bhattacharyya, Srinivas Ramachandran, Shantanu Sharma, Wimal Pathmasiri, Candice L. King, Irene Baskerville-Abraham, Gunnar Boysen, James A. Swenberg, Sharon L. Campbell, Nikolay V. Dokholyan, et al.

    The differences in efficacy and molecular mechanisms of platinum anti-cancer drugs cisplatin (CP) and oxaliplatin (OX) are thought to be partially due to the differences in the DNA conformations of the CP and OX adducts that form on adjacent guanines on DNA, which in turn influence the binding of damage-recognition proteins that control downstream effects of the adducts. Here we report a comprehensive comparison of the structural distortion of DNA caused by CP and OX adducts in the TGGT sequence context using nuclear magnetic resonance (NMR) spectroscopy and molecular dynamics (MD) simulations. When compared to our previous studies in other sequence contexts, these structural studies help us understand the effect of the sequence context on the conformation of Pt-GG DNA adducts. We find that both the sequence context and the type of Pt-GG DNA adduct (CP vs. OX) play an important role in the conformation and the conformational dynamics of Pt-DNA adducts, possibly explaining their influence on the ability of many damage-recognition proteins to bind to Pt-DNA adducts.


  • Open Access

    Structural basis for the sequence-dependent effects of platinum–DNA adducts

    by Srinivas Ramachandran, Brenda R. Temple, Stephen G. Chaney, Nikolay V. Dokholyan

    The differences in efficacy and molecular mechanisms of platinum based anti-cancer drugs cisplatin (CP) and oxaliplatin (OX) have been hypothesized to be in part due to the differential binding affinity of cellular and damage recognition proteins to CP and OX adducts formed on adjacent guanines in genomic DNA. HMGB1a in particular exhibits higher binding affinity to CP- GG adducts, and the extent of discrimination between CP- and OX- GG adducts is dependent on the bases flanking the adducts. However, the structural basis for this differential binding is not known. Here, we show that the conformational dynamics of CP- and OX- GG adducts are distinct and depend on the sequence context of the adduct. Molecular dynamics simulations of the Pt- GG adducts in the T GG A sequence context revealed that even though the major conformations of CP- and OX- GG adducts were similar, the minor conformations were distinct. Using the pattern of hydrogen bond formation between the Pt–ammines and the adjacent DNA bases, we identified the major and minor conformations sampled by Pt–DNA. We found that the minor conformations sampled exclusively by the CP- GG adduct exhibit structural properties that favor binding by HMGB1a, which may explain its higher binding affinity to CP- GG adducts, while these conformations are not sampled by OX- GG adducts because of the constraints imposed by its cyclohexane ring, which may explain the negligible binding affinity of HMGB1a for OX- GG adducts in the T GG A sequence context. Based on these results, we postulate that the constraints imposed by the cyclohexane ring of OX affect the DNA conformations explored by OX- GG adduct compared to those of CP- GG adduct, which may influence the binding affinities of HMG-domain proteins for Pt- GG adducts, and that these conformations are further influenced by the DNA sequence context of the Pt- GG adduct.


  • Differences in Conformation and Conformational Dynamics Between Cisplatin and Oxaliplatin DNA Adducts

    by Stephen G. Chaney, Srinivas Ramachandran, Shantanu Sharma, Nikolay V. Dokholyan, Brenda Temple, Debadeep Bhattacharyya, Yibing Wu, Sharon Campbell


  • Molecular Dynamic Simulations of Cisplatin- and Oxaliplatin-d(GG) Intrastand Cross-links Reveal Differences in their Conformational Dynamics

    by Shantanu Sharma, Peng Gong, Brenda Temple, Debadeep Bhattacharyya, Nikolay V. Dokholyan, Stephen G. Chaney


  • Solution Structures of a DNA Dodecamer Duplex with and without a Cisplatin 1,2-d(GG) Intrastrand Cross-Link: Comparison with the Same DNA Duplex Containing an Oxaliplatin 1,2-d(GG) Intrastrand Cross-Link,

    by Yibing Wu, Debadeep Bhattacharyya, Candice L. King, Irene Baskerville-Abraham, Sung-Ho Huh, Gunnar Boysen, James A. Swenberg, Brenda Temple, Sharon L. Campbell, Stephen G. Chaney

    Proteins that discriminate between cisplatin−DNA adducts and oxaliplatin−DNA adducts are thought to be responsible for the differences in tumor range, toxicity, and mutagenicity of these two important chemotherapeutic agents. However, the structural basis for differential protein recognition of these adducts has not been determined and could be important for the design of more effective platinum anticancer agents. We have determined high-resolution NMR structures for cisplatin−GG and undamaged DNA dodecamers in the AGGC sequence context and have compared these structures with the oxaliplatin−GG structure in the same sequence context determined previously in our laboratory. This structural study allows the first direct comparison of cisplatin−GG DNA and oxaliplatin−GG DNA solution structures referenced to undamaged DNA in the same sequence context. Non-hydrogen atom rmsds of 0.81 and 1.21 were determined for the 15 lowest-energy structures for cisplatin−GG DNA and undamaged DNA, respectively, indicating good structural convergence. The theoretical NOESY spectra obtained by back-calculation from the final average structures showed excellent agreement with the experimental data, indicating that the final structures are consistent with the NMR data. Several significant conformational differences were observed between the cisplatin−GG adduct and the oxaliplatin−GG adduct, including buckle at the 5‘ G6·C19 base pair, opening at the 3‘ G7·C18 base pair, twist at the A5G6·T20C19 base pair step, slide, twist, and roll at the G6G7·C19C18 base pair step, slide at the G7C8·C18G17 base pair step, G6G7 dihedral angle, and overall bend angle. We hypothesize that these conformational differences may be related to the ability of various DNA repair proteins, DNA binding proteins, and DNA polymerases to discriminate between cisplatin−GG and oxaliplatin−GG adducts.


  • Recognition and processing of cisplatin- and oxaliplatin-DNA adducts

    by Stephen G. Chaney, Sharon L. Campbell, Ekaterina Bassett, Yibing Wu


  • Protein interactions with platinum–DNA adducts: from structure to function

    by Stephen G. Chaney, Sharon L. Campbell, Brenda Temple, Ekaterina Bassett, Yibing Wu, Mihir Faldu


  • Frameshifts and deletions during in vitro translesion synthesis past Pt–DNA adducts by DNA polymerases β and η

    by Ekaterina Bassett, Alexandra Vaisman, Kristen A. Tropea, Chad M. McCall, Chikahide Masutani, Fumio Hanaoka, Stephen G. Chaney


    • 15 August 2002
      • Vol. 22  (4) , 2301-9

    Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity.

    by Stacy S Shord, Stephen A Bernard, Celeste Lindley, Andrew Blodgett, Viral Mehta, Mary Ann Churchel, Michael Poole, Scott L Pescatore, Feng R Luo, Stephen G Chaney

    Both oxaliplatin and ormaplatin undergo biotransformation to Pt(dach)Cl2 with studies suggesting a predictive relationship between systemic exposure to Pt(dach)Cl2 and the severity of the delayed sensory neuropathy associated with ormaplatin. Studies characterizing the pharmacokinetic parameters of oxaliplatin and Pt(dach)Cl2 in humans have not been reported. This study was conducted to characterize the pharmacokinetic parameters of oxaliplatin and Pt(dach)Cl2 and to determine the extent to which oxaliplatin undergoes biotransformation to Pt(dach)Cl2 in humans. Ten adult patients with metastatic colon cancer received oxaliplatin with or without fluorouracil-based chemotherapy. Blood samples were obtained during cycles 1 and 2. Total platinum, oxaliplatin and Pt(dach)Cl2 in the plasma ultrafiltrate were measured using high performance liquid chromatography and atomic absorption spectrometry. All patients underwent a thorough neurological evaluation after each cycle. The median steady-state concentration (C(SS)) (interquartile range, 25% to 75%) for oxaliplatin 85 mg/m2 was 0.33 microg Pt/ml (0.28 to 0.38 microg Pt/ml). The area under the curve (AUC) was 0.79 microg Pt/ml/h (0.62 to 0.88 microg Pt/ml/h) and the elimination half-life was 0.32 h (0.27 to 0.46 h). The median C(SS) for Pt(dach)Cl2 was 0.008 microg Pt/ml (0.004 to 0.014 microg Pt/ml). The C(SS) ratio of oxaliplatin to Pt(dach)Cl2 was 31 (24 to 51). All patients reported acute cold-induced neuropathy following cycles 1 and 2. Only two patients reported delayed sensory neuropathy (grade 1). The parent drug oxaliplatin is the major active platinum complex detected in plasma ultrafiltrate for at least the first few hours following oxaliplatin infusion in humans. Therefore, the plasma biotransformation products of oxaliplatin are unlikely to contribute to its efficacy or toxicity. In particular, plasma Pt(dach)Cl2 is unlikely to significantly contribute to the delayed sensory neuropathy associated with oxaliplatin, since only a limited amount (<3%) of oxaliplatin undergoes biotransformation to Pt(dach)Cl2.